Teva (TEVA) EVP Matthew Shields exercises RSUs and sells vested shares

Rhea-AI Filing Summary

Teva Pharmaceutical Industries executive Matthew Shields exercised 17,295 restricted share units into ordinary shares and, on the same day, sold 17,295 ordinary shares in an open-market transaction at a weighted average price of $31.6684. The sale was executed under a Rule 10b5-1 trading plan adopted on November 10, 2025 and included shares sold to cover tax withholding obligations tied to vesting. Following these transactions, Shields directly holds 9,989 ordinary shares and 51,887 restricted share units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shields Matthew

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Global Operations

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/05/2026		M		17,295	A	(2)	27,284	D
Ordinary Shares(1)	03/05/2026		S(3)		17,295(4)	D	$31.6684(5)	9,989	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/05/2026		M			17,295	(6)	(6)	Ordinary Shares(1)	17,295	$0	51,887	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

4. Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. Restricted share units were granted on March 5, 2025, with 17,295 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029.

	/s/ Dov Bergwerk as attorney-in-fact for Matthew Shields	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Teva (TEVA) executive Matthew Shields report?

Matthew Shields exercised 17,295 restricted share units into ordinary shares and sold 17,295 ordinary shares. The sale was an open‑market transaction under a pre‑arranged Rule 10b5‑1 trading plan and related to shares that vested from a prior equity grant.

At what price were Matthew Shields’ Teva (TEVA) shares sold in this Form 4?

The reported sale used a weighted average price of $31.6684 per Teva ordinary share. Footnotes state the shares were sold in multiple transactions between $31.26 and $32.34, with detailed trade breakdowns available upon request from the reporting person.

How many Teva (TEVA) shares does Matthew Shields own after the reported Form 4 transactions?

After the transactions, Matthew Shields directly holds 9,989 Teva ordinary shares and 51,887 restricted share units. The ordinary share figure reflects completion of the same‑day sale, while the restricted share units remain as equity awards that may settle in shares or cash at vesting.

Were Matthew Shields’ Teva (TEVA) share sales pre‑planned under Rule 10b5‑1?

Yes. A footnote explains the reported sale was effected under a Rule 10b5‑1 trading plan adopted by Matthew Shields on November 10, 2025. Such plans pre‑schedule trades, allowing executives to systematically sell shares regardless of later possession of material nonpublic information.

Why did Matthew Shields sell Teva (TEVA) shares upon RSU vesting?

A footnote states Shields sold all shares that vested from his restricted share units, including shares used to cover tax withholding obligations. This means part or all of the sale proceeds effectively satisfied taxes triggered by the equity award’s vesting event.

What are the key terms of Matthew Shields’ Teva (TEVA) restricted share units?

Each restricted share unit represents a contingent right to receive, at settlement, one Teva ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. A prior grant scheduled vesting in annual tranches from March 2026 through March 2029.